Aardvark Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases. Its lead product candidate is ARD-101, an oral gut-restricted small-molecule agonist of certain targeting bitter taste receptors expressed in the gut lumen, which is in the Phase 3 clinical trial for hyperphagia associated with Prader-Willi Syndrome, as well as in the Phase 2 clinical trial for hyperphagia associated with acquired hypothalamic obesity resultant from the treatment of craniopharyngioma, including surgery or radiation. The company is also developing ARD-201, which is in the Phase 1 clinical trial for the treatment of obesity. Aardvark Therapeutics, Inc. was incorporated in 2017 and is headquartered in San Diego, California. Show more
Location: 4370 La Jolla Village Drive, San Diego, CA, 92122, United States | Website: https://aardvarktherapeutics.com | Industry: Biotechnology | Sector: Healthcare
Market Cap
263.9M
52 Wk Range
$4.88 - $19.58
Previous Close
$12.60
Open
$12.65
Volume
38,067
Day Range
$12.11 - $12.65
Enterprise Value
142.8M
Cash
151.3M
Avg Qtr Burn
-6.821M
Insider Ownership
14.22%
Institutional Own.
49.49%
Qtr Updated
03/31/25
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|